StemCellPatents.com Recently Added Stem Cell Patents

Treatment of muscular dystrophy with cord blood cells

Viacell, Inc. (Worchester, MA); The General Hospital Corporation (Boston, MA) — 2008-07-23T16:38:36-05:00

Cord blood stem cells are currently approved only for hematopoietic reconstitution, however numerous experimental uses are being reported. Given that cord blood stem cells have been reported to possess pluripotent characteristics, a wide variety of new indications are being developed. For example, a clinical trial is currently being performed using autologous cord...

Mesenchymal precursor cell

Angioblast Systems, Incorporated (New York, NY) — 2008-07-15T15:17:05-05:00

Mesenchymal stem cell therapy is rapidly becoming a clinical reality. The beauty of this cell population is that it can be used in an "off the shelf" manner and does not appear to have many safety issues. Mesenchymal stem cells from the bone marrow have been patented by Osiris, whereas cells similar to mesenchymal stem cells have been found in other tissues, for example in the cord blood and most...

Telomerase promoters sequences for screening telomerase modulators

Geron Corporation (Menlo Park, CA) — 2008-05-30T21:31:29-05:00

Division of most mammalian cells is accompanied by reduction in the length of telomeres, which is responsible in part for cellular senescence and death. Some cells, particularly stem cells and cancer cells, express the enzyme telomerase and are not restricted by the "Hayflick Limit". Some data exists to support the concept that telomerase can not only immortalize cells, but can do so...

Compounds to promote regeneration of bone marrow

Zoltan Laboratories, LLC (Austin, MN) — 2007-03-23T16:56:10-05:00

This patent covers the use of heterocyclic trialkyl ammonium-containing compounds for stimulation of bone marrow proliferation and differentiation after myeloablation or other insults to the hematopoietic stem cell compartment. The toxicity profile of the compounds appears favorable.

Data in the examples section demonstrates protection from cyclophosphamide destruction of the bone marrow, as well as radiation and several other models.

Other stimulators of...

Methods of producing pancreatic hormones

Cythera, Inc. (San Diego, CA) — 2007-03-02T16:03:36-05:00

The company Novocell (merged from Cythera, BresaGen, and Novocell) has been strategically developing an IP portfolio covering numerous aspects of treating diabetes.

Having IP on endoderm, as well as encapsulation technologies, the company recently was issued the current patent covering generation of insulin producing cells from embryonic stem cells.

The first independent claim covers: "A method for producing insulin, said...

Methods to mobilize progenitor/stem cells

Anormed, Inc. (Langley, CA) — 2007-02-04T17:05:35-05:00

The reason why bone marrow cells home into the bone after intravenous administration is because a continuous production of Stromal Derived Factor-1 (SDF-1) by the bone marrow stromal compartments. The gradient of SDF-1 is also retains the early CD34+ bone marrow hematopoietic stem cells in the bone marrow. The current patent covers compositions of matter that inhibit the interaction between SDF-1 and its...

Injectable hyaluronic acid derivative with pharmaceuticals/cells

Fidia Advanced Biopolymers, SRL. (Abano Terme, IT) — 2007-01-06T15:18:24-05:00

This patent covers specific types of hyaluronic acid derivatives that are useful for administering cells into a soft tissue that is injured. Specifically, the patent is useful for treatment of intra-articular injuries by providing a means to administer cells so that the cells will be able to take the particular in vivo shape that is unique to the patient being treated. The patent has 2 independent claims. The first is a method of treatment claim, which provides at least one type of...

SCF antibody compositions and methods of using the same

Amgen Inc. (Thousand Oaks, CA) — 2006-10-16T17:43:19-05:00

Amgen has developed a strong patent portfolio covering the hematopoietic stimulating cytokine called Stem Cell Factor. Subsequently it was demonstrated that stem cell factor is capable of stimulating a variety of other stem cells in addition to hematopoietic stem cells. As part of its IP portfolio covering stem cell factor, Amgen has patented antibodies to the cytokine. This current patent covers polyclonal and monoclonal antibodies to stem cell factor from human or from other...

Methods of use of FGF homologs

ZymoGenetics, Inc. (Seattle, WA) — 2006-10-16T12:53:04-05:00

This patent covers the use of zFGF-5 (currently known as FGF-18) for expansion in vitro and in vivo of chondrocytes and neural stem cells. According to the Zymogenetics website, FGF-18 is out-licensed to Serono for use in cartilage repair and stroke. The product is in preclinical phases of testing. While the specification provides numerous uses for FGF-18, the claims are restricted to one independent claim...

Cosmetic compositions

Natural Beauty Bio-Technology Limited (Taipei, TW) — 2006-03-27T17:20:52-05:00

The current patent covers a cosmetic generated using a variant of stromal derived factor (SDF-1) which the inventors termed stem cell active factor (SCAF). The natural function of SDF-1 is to call in stem cells to injured tissue, for example, after a heart attack there is a surge of SDF-1 which is involved in mediating mobilization of stem cells from the bone marrow and causing them to home to the injured heart muscle in an attempt to heal it. SDF-1 is...

Method of generating human retinal progenitors from embryonic stem cells

University of Washington (Seattle, WA) — 2006-02-22T17:11:37-05:00

This patent covers the generation of retinal progenitor cells from embryonic stem cells. Neural stem cells have previously been demonstrated to have ability to differentiate into retinal tissue, as well as embryonic stem cell derived cells.

The current patent covers a methodology involving the generation of embryoid bodies in medium lacking bFGF and supplemented with IGF-1, Dkk-1, and Noggin. After...

Compositions and methods for promoting attachment of cells of endothelial cell lineage to medical devices

Affinergy, Inc. (Durham, NC) — 2006-01-11T00:49:11-05:00

Lack of proper endothelialization of vascular grafts can cause a variety of problems such as restenosis or thrombosis. The current patent covers a coating for medical devices in which one side of the coating binds to the metallic surface of the device and the other side contains peptides that bind to endothelium or endothelial precursor cells.

This patent is useful for makers of stents and other devices that come into contact with blood...

Monoclonal antibodies to mesenchymal stem cells

Seoul National University Industry Foundation (Seoul, KR) — 2006-01-10T04:16:37-05:00

This patent covers antibodies that bind to mesenchymal stem cells. The antibodies are deposited as hybridomas under accession numbers KCLRF-BP-000123, KCLRF-BP-000124 or KCLRF-BP-000125 at the Korean Cell Line Research Foundation (Cancer Research Institute, Seoul National University, College of Medicine, 28 Yongondong, Chongno-Gu, Seoul, 110-744, Korea). The antigen appears to be about 130 kDa.

It is important to find markers of mesenchymal stem cells since this may lead...

Implantable cell/tissue-based biosensing device

Medtronic, Inc. (Minneapolis, MN) — 2005-12-29T18:24:49-05:00

The current patent covers a device useful for detecting chemicals in a patient, with the device being implantable. Practically the device claimed is used for implantation into the heart and provides information via electrical signals as to the chemical environment based on changes to the "biosensing" cells.

In its first claim, the patent covers "a biosensor device for sensing an analyte in a patient, the biosensor device comprising: a biosensing...

Method of treating brain tissue damages

Academia Sinica (Taipei, TW) — 2005-11-21T20:39:26-05:00

It is known that various endogenous repair processes exist after ischemic injury to the brain. For example, in stroke patients, there is a correlation between improvement of neurological function and amount of circulating stem cells. Attempts are being made to augment endogenous repair processes by administration of agents such as PACAP, prolactin, or

Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin

Stem Cell Therapeutics Inc. (Calgary, Alberta, Canada) — 2005-09-27T16:04:55-05:00

This patent covers the use of prolactin alone or in combinations with other agents for enhancing formation of oligodendrocytes in vivo. It is assigned to the company Stem Cell Therapeutics, out of Calgary Canada, who is currently using hCG and EPO for treatment of strokes in Phase II clinical trials. Other patents owned by Stem Cell Therapeutics include #7,048,934 which covers prolactin and EPO for stimulation of neurogenesis, and #

Sirtuin modulating compounds

Sirtris Pharmaceuticals, Inc. (Cambridge, MA) — 2005-08-04T21:21:21-05:00

This patent covers the composition of matter for novel compounds that are useful for modulation of sirtuins. Sirtuins are a class of proteins that act as histone deacetylase inhibitors. Why there is great interest in modulating these enzymes is because the SIR2 members of this family have been demonstrated to play a critical role in life extension associated with caloric restriction. This patent is assigned to the company Sirtris, which recently went public...

Stromal antigen-presenting cells and use thereof

McGill University (Montreal, CA) — 2005-05-31T06:14:11-05:00

Mesenchymal stem cells are known to possess a variety of immune modulatory activities such as suppression of allogeneic responses, as well as induction of T regulatory cells. Mechanisms include expression of IDO and HLA-G. Mesenchymal stem cells have been demonstrated effective in patients with heart failure and are clinically in trials for

Combined effects of nutrients on proliferation of stem cells

University of South Florida (Tampa, FL) — 2005-05-02T02:24:25-05:00

Manipulation of the stem cell compartment using nutritional supplements offers a rapid way of commercially entering the area of regenerative medicine without having to undergo full-blown FDA clinical trials. Examples of such patents include #7,338,676 which teaches extracts of pinecones can induce stem cell differentiation into dendritic cells, patent #7,419,690 covering the use of yam extracts to activate hematopoietic...

In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic patients

Istituto Superiore di Sanita (Rome, IT) — 2005-02-26T00:00:00-05:00

This patent teaches how to generate large quantities of erythroid cells in vitro. This is useful for nuclear disasters or situations where large quantities of red blood cells are needed for transfusion purposes. This is a very interesting invention since it uses as the starting population blood cells and not bone marrow. The invention has 1 independent claim covering the method of generating erythroid cells. Specifically, the claim covers taking blood cells of a "low density"...